JP5876826B2 - 糖尿病前症及び２型糖尿病におけるアポリポタンパク質ｃｉｉｉ - Google Patents

糖尿病前症及び２型糖尿病におけるアポリポタンパク質ｃｉｉｉ Download PDF

Info

Publication number
JP5876826B2
JP5876826B2 JP2012519652A JP2012519652A JP5876826B2 JP 5876826 B2 JP5876826 B2 JP 5876826B2 JP 2012519652 A JP2012519652 A JP 2012519652A JP 2012519652 A JP2012519652 A JP 2012519652A JP 5876826 B2 JP5876826 B2 JP 5876826B2
Authority
JP
Japan
Prior art keywords
apociii
diabetes
type
biological sample
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012519652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533066A (ja
JP2012533066A5 (enExample
Inventor
エー． キールナン，アーバン
エー． キールナン，アーバン
ネデルコフ，ドブリン
Original Assignee
イントリンジック バイオプローブズ，インコーポレイテッド
イントリンジック バイオプローブズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イントリンジック バイオプローブズ，インコーポレイテッド, イントリンジック バイオプローブズ，インコーポレイテッド filed Critical イントリンジック バイオプローブズ，インコーポレイテッド
Publication of JP2012533066A publication Critical patent/JP2012533066A/ja
Publication of JP2012533066A5 publication Critical patent/JP2012533066A5/ja
Application granted granted Critical
Publication of JP5876826B2 publication Critical patent/JP5876826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2012519652A 2009-07-07 2010-07-03 糖尿病前症及び２型糖尿病におけるアポリポタンパク質ｃｉｉｉ Active JP5876826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22350209P 2009-07-07 2009-07-07
US61/223,502 2009-07-07
PCT/US2010/040998 WO2011005718A1 (en) 2009-07-07 2010-07-03 Apolipoprotein ciii in pre- and type 2 diabetes

Publications (3)

Publication Number Publication Date
JP2012533066A JP2012533066A (ja) 2012-12-20
JP2012533066A5 JP2012533066A5 (enExample) 2013-05-30
JP5876826B2 true JP5876826B2 (ja) 2016-03-02

Family

ID=43427312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519652A Active JP5876826B2 (ja) 2009-07-07 2010-07-03 糖尿病前症及び２型糖尿病におけるアポリポタンパク質ｃｉｉｉ

Country Status (5)

Country Link
US (2) US20110008901A1 (enExample)
EP (1) EP2451466B1 (enExample)
JP (1) JP5876826B2 (enExample)
CN (1) CN102481319A (enExample)
WO (1) WO2011005718A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes
US9125255B2 (en) 2012-05-03 2015-09-01 Abl Ip Holding Llc Networked architecture for system of lighting devices having sensors, for intelligent applications
US9901562B2 (en) 2013-04-04 2018-02-27 Lycored Ltd. Anti-inflammatory omega-3 synergistic combinations
BR112020008514A2 (pt) * 2017-10-31 2020-10-20 Staten Biotechnology B.V. anticorpos anti-apoc3 e métodos de uso dos mesmos
CN114354827A (zh) * 2022-03-21 2022-04-15 天津云检医疗器械有限公司 代谢标志物及其在制备2型糖尿病的风险预测试剂盒中的应用和试剂盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164818A1 (en) * 1995-05-23 2002-11-07 Gruber Karl F. Mass spectrometric immunoassay analysis of specific proteins and variants present in various biological fluids
JP2005503537A (ja) * 2001-01-17 2005-02-03 エー． タブス，ケモンズ 生体分子分析用ハイ・スループット統合システム
CA2434699A1 (en) * 2001-01-17 2002-10-17 Randall W. Nelson An integrated high throughput system for the analysis of biomolecules
US6677303B2 (en) * 2001-04-30 2004-01-13 Syn X Pharma Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons
US9062306B2 (en) * 2003-04-29 2015-06-23 Biocrine Ab Methods for identifying compounds for treating type 1 diabetes
US20070087448A1 (en) * 2004-02-16 2007-04-19 Nelsestuen Gary L Biological profiles and methods of use
US8343534B2 (en) * 2004-04-23 2013-01-01 The Procter & Gamble Company Tissue including a volatile rhinological composition
US20060110082A1 (en) * 2004-11-24 2006-05-25 Sauer-Danfoss Inc. Compact unitized cradle swashplate bearing
JPWO2006073195A1 (ja) * 2005-01-07 2008-06-12 敏一 吉川 糖尿病の予知・診断方法および糖尿病予知・診断用キット
CN101166981A (zh) * 2005-04-11 2008-04-23 阿斯利康(瑞典)有限公司 一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒
US20070055341A1 (en) * 2005-08-26 2007-03-08 Vascular And Endovascular Surgical Technologies, Inc. Endograft
US20070112055A1 (en) * 2005-09-30 2007-05-17 Glenmark Pharmaceuticals Limited Crystalline forms of almotriptan and processes for their preparation
JP5688829B2 (ja) * 2005-11-11 2015-03-25 敏一 吉川 示差的な糖尿病の予知・診断方法および糖尿病予知・診断用キット
EP2005172A4 (en) * 2006-03-23 2009-05-06 Emelita De Guzman Breyer APOLIPOPROTEIN-FINGERPRINT PROCESS
JP2009537812A (ja) * 2006-05-15 2009-10-29 デジラブ インコーポレーテッド ２型糖尿病プリフォームのバイオマーカー、及び２型糖尿病プリフォームの存在又は不在を検出する方法
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes

Also Published As

Publication number Publication date
US20110008901A1 (en) 2011-01-13
WO2011005718A1 (en) 2011-01-13
JP2012533066A (ja) 2012-12-20
EP2451466A4 (en) 2012-12-12
CN102481319A (zh) 2012-05-30
EP2451466B1 (en) 2016-03-30
EP2451466A1 (en) 2012-05-16
US20150212100A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
Shao et al. Mass spectrometry-based proteomic quest for diabetes biomarkers
Kiernan et al. Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay
JP2011515680A (ja) 糖尿病のためのバイオマーカーおよびアッセイ
US20150090010A1 (en) Method for diagnosing heart failure
Joshi et al. Recent progress in mass spectrometry-based urinary proteomics
CN112903885B (zh) 一种筛查糖尿病的联合型代谢标志物的应用及其试剂盒
JP5876826B2 (ja) 糖尿病前症及び２型糖尿病におけるアポリポタンパク質ｃｉｉｉ
WO2021232211A1 (zh) 诊断肾病的标志物以及诊断方法
CN115327129A (zh) 一种血浆分子标志物犬尿氨酸在早期心力衰竭检测中的应用
WO2024109767A1 (zh) 基于粪便代谢物的阿尔兹海默症标志物及其应用
CN115112776B (zh) 联合标志物及在诊断心房颤动中应用及诊断试剂或试剂盒
JP5748751B2 (ja) 糖尿病前症及び２型糖尿病における血清アミロイドの表現型比率
CN112599239B (zh) 代谢物标志物及其在脑梗死诊断中的应用
CN112305122B (zh) 代谢物标志物及其在疾病中的应用
JP6128631B2 (ja) 糖尿病性腎症鑑別用マーカー及びその用途
WO2024109768A1 (zh) 基于血液代谢物的阿尔茨海默症标志物及其应用
CN112599237B (zh) 一种生物标志物及其在脑梗死诊断中的应用
CN118275706A (zh) 用于诊断肺癌分型的代谢标志物
CN114137192B (zh) 7-甲基黄嘌呤作为检测靶点在制备2型糖尿病高危个体筛查试剂盒中的应用
CN117192009A (zh) 湿热下注型痛风病生物标记物的发现及应用
CN112305089B (zh) 一种慢性肾病诊断生物标记物及其应用
CN113655141A (zh) 一种早期预警重症急性胰腺炎的血清极性小分子预测模型与应用
CN115469026B (zh) 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途
KR102780084B1 (ko) 대사체를 유효성분으로 포함하는 방광암의 진단용 조성물
JPH04505218A (ja) 糖尿病性異常を予言する物質の定量分析法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131211

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160122

R150 Certificate of patent or registration of utility model

Ref document number: 5876826

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250